World Trade Factory™

Jazz Gains From Ziihera Data, Upside Seen as Priced In, UBS Says

Jazz Gains From Ziihera Data, Upside Seen as Priced In, UBS Says

Jazz Pharmaceuticals received a boost from positive topline data from a late-stage study of Ziihera in gastro-esophageal adenocarcinoma, which uplifts the company's oncology revenue outlook but is...

Read Full Article →

📱 Tip: Tap the 🔗 Share icon in Safari and choose Add to Home Screen to install World Trade Factory.